Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats

Toxicology Letters

Volumn 178, Issue 1, 2008, Pages 9-19

  Pereverzeva, E ^a   Treschalin, I ^a   Bodyagin, D ^a   Maksimenko, O ^b   Kreuter, J ^c   Gelperina, S ^b  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b Nanosystem LTD   (Russian Federation)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Cardiotoxicity; Doxorubicin; Nanoparticles; Poly(butyl cyanoacrylate); Rat; Testicular toxicity

Indexed keywords

DOXORUBICIN; NANOPARTICLE; POLY(BUTYL CYANOACRYLATE); POLYSORBATE 80; SURFACTANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD EXAMINATION; BODY WEIGHT; CARDIOTOXICITY; CHEMICAL ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COATING; DRUG FORMULATION; DRUG TOLERANCE; DYNAMICS; FEMALE; FOLLOW UP; HEART; HISTOLOGY; INJECTION; LIVER; LUNG; MALE; MORPHOLOGY; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; SPLEEN; TESTIS; TESTIS DISEASE; TOXICOLOGY; URINALYSIS; WISTAR RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; ENBUCRILATE; EXCIPIENTS; FEMALE; INJECTIONS, INTRAVENOUS; LIVER; LUNG; MALE; MYOCARDIUM; NANOPARTICLES; POLYSORBATES; RATS; RATS, WISTAR; SPLEEN; TESTIS;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 41949107530     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.01.020     Document Type: Article

References (23)

1. Couvreur P., Kante B., Grislain L., Roland M., and Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J. Pharm. Sci. 71 (1982) 790-792
2. Couvreur P., Grislain L., Lenaerts V., Brasseur F., Guiot P., and Biernacki A. Biodegradable polymeric nanoparticles as drug carrier for antitumor agents. In: Guiot P., and Couvreur P. (Eds). Polymeric Nanoparticles and Microspheres (1986), CRC Press, Boca Raton, FL 27-93
3. Garcia-Garcia E., Andrieux K., Gil S., and Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?. Int. J. Pharm. 298 2 (2005) 274-292
4. Gelperina S.E., Khalansky A.S., Skidan I.N., Smirnova Z.S., Bobruskin A.I., Severin S.E., Turowski B., Zanella F.E., and Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126 (2002) 131-141
5. Gelperina S. Brain delivery by nanoparticles. In: Gupta R.B., and Kompella U.B. (Eds). Nanoparticle Technology for Drug Delivery, Drugs and the Pharmaceutical Sciences 159 (2006), Marcel Dekker, New York 273-318
6. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Ya., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 (1999) 1564-1569
7. Julicher R.H., Sterrenberg L., Haenen G.R., Bast A., and Noordhoek J. Sex differences in the cellular defence system against free radicals from oxygen or drug metabolites in rat. Arch. Toxicol. 56 2 (1984) 83-86
8. Julicher R.H., Sterrenberg L., Haenen G.R., Bast A., and Noordhoek J. The effect of chronic Adriamycin treatment on heart kidney and liver tissue of male and female rat. Arch. Toxicol. 61 4 (1988) 275-281
9. Kreuter J., Alyautdin R.N., Kharkevich D.A., and Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674 (1995) 171-174
10. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
11. Kreuter J. Nanoparticulate carriers for drug delivery to the brain. In: Torchilin V.P. (Ed). Nanoparticles as Drug Carriers (2006), Imperial College Press, London 527-547
12. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautdin R., von Briesen H., and Begley D.J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20 (2003) 409-416
13. Lenaerts V., Nagelkerke J.F., Van Berkel T.J., Couvreur P., Grislain L., Roland M., and Speiser P. In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchymal cells. J. Pharm. Sci. 73 7 (1984) 980-982
14. Mazue G., Iatropoulos M., Imondi A., Castellino S., Brughera M., Podesta A., Della Torre P., and Moneta D. Anthracyclines: a review of general and special toxicity studies. Int. J. Oncol. 7 (1995) 713-726
15. Pereverzeva E., Treschalin I., Bodyagin D., Maksimenko O., Langer K., Dreis S., Asmussen B., Kreuter J., and Gelperina S. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity. Int. J. Pharm. 337 (2007) 346-356
16. Petri B., Bootz A., Khalansky A., Hekmatara T., Muller R., Uhl R., Kreuter J., and Gelperina S. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Control Rel. 117 (2007) 51-58
17. Singal P.K., Li T., Kumar D., Danelisen I., and Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol. Cell Biochem. 207 (2000) 77-86
18. Stan A.C., Casares S., Radu D., Walter G.F., and Brumeanu T.D. Doxorubicin-induced cell death in highly invasive human gliomas. Anticancer Res. 19 (1999) 941-950
19. Steiniger S.C.J., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., Severin S.E., Uhl R., Kock M., Geiger K.D., and Gelperina S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109 (2004) 759-767
20. Tsunenari I., Kawachi M., Matsumaru T., and Katsuki S. Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 10). Testicular toxicity of Adriamycin observed 2 and 4 weeks after a single intravenous administration. J. Toxicol. Sci. 25 (2000) Spec No: 101-115
21. van Hoesel Q.G., Steerenberg P.A., Dormans J.A., de Jong W.H., de Wildt D.J., and Vos J.G. Time-course study on doxorubicin-induced nephropathy and cardiomyopathy in male and female LOU/M/Wsl rats: lack of evidence for a causal relationship. J. Natl. Cancer Inst. 76 2 (1986) 299-307
22. Walter K.A., Tamargo R.J., Olivi A., Burger P.C., and Brem H. Intratumoral chemotherapy. Neurosurgery 37 (1995) 1128-1145
23. Zucchi R., and Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr. Med. Chem. - Anti-Cancer Agents 3 (2003) 151-171